The ImmuBridge™ platform embodies cutting-edge advancements in oncology and immunotherapy. Leveraging this platform, we can develop trispecific antibodies targeting a variety of immune and tumor cell antigens to activate diverse immune mechanisms, fostering precise and efficient cancer therapeutics.
Opret nyt tilbud
Rapporter denne side
Sats Trispecific Antibody Development
Opret job
Rediger tilbud
Tilføj niveau
Slet dit niveau
Er du sikker på, at du vil slette dette niveau?
Anmeldelser
For at sælge dit indhold og dine indlæg, start med at oprette et par pakker. Indtægtsgenerering
